336 related articles for article (PubMed ID: 16801435)
1. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Hakki M; Staab JF; Marr KA
Antimicrob Agents Chemother; 2006 Jul; 50(7):2522-4. PubMed ID: 16801435
[TBL] [Abstract][Full Text] [Related]
2. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
3. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
[TBL] [Abstract][Full Text] [Related]
4. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
[TBL] [Abstract][Full Text] [Related]
5. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
8. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
[TBL] [Abstract][Full Text] [Related]
9. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.
Breit SM; Hariprasad SM; Mieler WF; Shah GK; Mills MD; Grand MG
Am J Ophthalmol; 2005 Jan; 139(1):135-40. PubMed ID: 15652837
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
Kartsonis N; Killar J; Mixson L; Hoe CM; Sable C; Bartizal K; Motyl M
Antimicrob Agents Chemother; 2005 Sep; 49(9):3616-23. PubMed ID: 16127030
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr.
Gil-Lamaignere C; Müller FM
Int J Antimicrob Agents; 2004 May; 23(5):520-3. PubMed ID: 15120736
[TBL] [Abstract][Full Text] [Related]
14. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.
Chamilos G; Lewis RE; Albert N; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Jun; 51(6):2257-9. PubMed ID: 17438060
[TBL] [Abstract][Full Text] [Related]
16. Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.
Cantón E; Pemán J; Gobernado M; Alvarez E; Baquero F; Cisterna R; Gil J; Martín-Mazuelos E; Rubio C; Sánchez-Sousa A; Serrano C
Antimicrob Agents Chemother; 2005 Apr; 49(4):1604-7. PubMed ID: 15793151
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro susceptibility of clinical isolates of Candida paparsilosis complex and other Candida species to caspofungin and anidulafungin by Etest.
Khan Z; Ahmad S; Joseph L; Chandy R; Theyyathel A
J Chemother; 2011 Apr; 23(2):97-101. PubMed ID: 21571626
[TBL] [Abstract][Full Text] [Related]
18. Acquired echinocandin resistance in a Candida krusei blood isolate confirmed by mutations in the fks1 gene.
Prigitano A; Esposito MC; Cogliati M; Pitzurra L; Santamaria C; Tortorano AM
New Microbiol; 2014 Apr; 37(2):237-40. PubMed ID: 24858652
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin in combination with amphotericin B against Candida glabrata.
Barchiesi F; Spreghini E; Fothergill AW; Arzeni D; Greganti G; Giannini D; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2005 Jun; 49(6):2546-9. PubMed ID: 15917570
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin.
Olver WJ; Scott F; Shankland GS
Med Mycol; 2006 Nov; 44(7):655-7. PubMed ID: 17071561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]